Flu vaccine research: overcoming 'original sin'

August 13, 2012
Flu vaccine research: overcoming 'original sin'

(Medical Xpress) -- Scientists studying flu vaccines have identified ways to overcome an obstacle called "original antigenic sin," which can impair immune responses to new flu strains.

Original antigenic sin (OAS) is a situation where the is fighting with obsolete weapons and has trouble adapting. After encountering one viral strain, and then a new one that is related to the first, the immune system can respond by making antibodies against the first strain, resulting in a less effective defense.

Researchers at Emory Vaccine Center have demonstrated in experiments with mice that OAS can be overcome by using a vaccine additive called an adjuvant, or by repeated immunization with the second viral strain. The results were published this week in .

The first author of the paper is postdoctoral fellow Jin Hyang Kim, who now works on influenza at the . The senior author is Joshy Jacob, PhD, associate professor of microbiology and immunology at Emory University School of Medicine.

The findings could be important when vaccinating individuals with weaker immune systems, such as people with , small children or the elderly, the authors write.

The influenza virus has become so widespread because it can infect a wide range of hosts such as pigs and birds, and because its genome is flexible, Jacob says. 

Influenza strains change their DNA in two ways. Antigenic drift occurs as a strain accumulates small mutations, which can help it escape from the host’s immune system. Antigenic shift occurs when two strains, possibly from different host species, swap DNA.

"Original antigenic sin is really a reflection of the agility of the influenza virus," he says. "OAS becomes a factor when the new circulating strain is a ‘drifted’ version of what came before. The old antibodies can’t neutralize the new virus, and that helps the new virus survive."

In a Journal of Immunology paper published in 2009, Jin and Jacob showed that OAS could impair the immune responses of mice exposed to two well-studied H1N1 : PR8, from 1934, and FM1, from 1947.

If mice are immunized first with inactivated PR8 virus and a month later FM1, and then exposed to live FM1, the lungs of the mice had higher viral levels than those that weren’t immunized first with PR8. This effect was even stronger after sublethal infection with live virus, rather than vaccination with inactivated virus.

In the new PNAS paper, Jin and colleagues demonstrated that combining the FM1 immunization with an adjuvant allows the mice to respond better to the live virus. The adjuvant is a squalene oil-in-water emulsion. Squalene is a vaccine additive licensed in European countries since the 1990s, but not approved for use in the United States. Surprisingly, the adjuvant could also improve immune responses when combined with the initial PR8 immunization.

"It appears that the is making the immune responses to the first viral strain broader, so that a wider range of antibody-producing cells are able to respond to the second strain," Jacob says.

The handicap of the twice-immunized mice against the second virus could also be overcome by a booster shot against the second . The authors write:

"Collectively, our findings imply that OAS could potentially be prevented in the naïve human population, especially children, by administering adjuvants with the first influenza vaccine. Alternatively, in the older population with prior exposure or vaccinations, original antigenic sin can be minimized by using adjuvants."

Explore further: Adjuvant combo shows potential for universal influenza vaccine

More information: Reference: J.H. Kim, W.G. Davis, S. Sambhara and J. Jacob. Strategies to alleviate original antigenic sin responses to influenza viruses. PNAS (2012). doi: 10.1073/pnas.0912458109

Related Stories

Adjuvant combo shows potential for universal influenza vaccine

June 8, 2011
Researchers at National Jewish Health have discovered how to prime a second arm of the immune system to potentially boost influenza vaccine effectiveness. A combination of two adjuvants, chemicals used to boost the effectiveness ...

Pandemic 2009 H1N1 vaccination produces antibodies against multiple flu strains

May 21, 2012
The pandemic 2009 H1N1 vaccine can generate antibodies in vaccinated individuals not only against the H1N1 virus, but also against other influenza virus strains including H5N1 and H3N2. This discovery adds an important new ...

Recommended for you

Discovery of potent parasite protein may lead to new therapeutic options for inflammatory bowel conditions

November 24, 2017
A single protein from a worm parasite may one day offer new therapeutic options for treating inflammatory bowel diseases like Crohn's or Ulcerative Colitis, that avoid the potentially serious side effects of current immunosuppressant ...

Druglike molecules produced by gut bacteria can affect gut, immune health

November 23, 2017
Stanford researchers found that manipulating the gut microbe Clostridium sporogenes changed levels of molecules in the bloodstreams of mice and, in turn, affected their health.

Study explores whole-body immunity

November 21, 2017
Over the next few months, millions of people will receive vaccinations in the hope of staving off the flu—and the fever, pain, and congestion that come with it.

Drug could cut transplant rejection

November 21, 2017
A diabetes drug currently undergoing development could be repurposed to help end transplant rejection, without the side-effects of current immunosuppressive drugs, according to new research by Queen Mary University of London ...

Atopic eczema—one size does not fit all

November 21, 2017
Researchers from the UK and Netherlands have identified five distinct subgroups of eczema, a finding that helps explain how the condition can affect people at different stages of their lives.

Breast milk found to protect against food allergy

November 20, 2017
Eating allergenic foods during pregnancy can protect your child from food allergies, especially if you breastfeed, suggests new research from Boston Children's Hospital. The study, published online today in the Journal of ...

1 comment

Adjust slider to filter visible comments by rank

Display comments: newest first

dogbert
not rated yet Aug 13, 2012
Squalene is not approved for use as an adjuvant in the US and probably should not be approved.

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.